Saul Meike
Saul Meike received her PhD in Pharmaceutical Chemistry from Goethe Universität Frankfurt in 2012. She has been a “Athene Young Investigator of the TU Darmstadt” since 2018. Her research aims to identify novel miR functionalities in various diseases and investigate their role in intercellular communication, which can be transferred to new treatment strategies. Currently, her lab investigates whether miR-574-5p is transferred within exosomes between cancer cells and cells of the tumor microenvironment to influence tumor progression using lung cancer and neuroblastoma as contrary tumor model systems.